Drug Use May Shift Under US Medicare Oncology Care Model; Here’s How

‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.

Off-label prescribing for oncology treatments and use of supportive care drugs may see some changes as a result of the Medicare Oncology Care Model, a large-scale experiment testing a new approach to payments for cancer care treatments and services now underway and involving more than 3,200 oncologists and about 155,000 beneficiaries nationwide.

Launched July 1, the model is a five-year modified bundling experiment aimed at improving the quality of care and lowering...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet